+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Hepatorenal Syndrome Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997609
  • Report
  • March 2020
  • Region: Global
  • 110 pages
  • Mordor Intelligence
1 of 4


  • Aetna Inc.
  • Baxter
  • Fuji Systems Corp
  • G Surgiwear Ltd
  • Johnson & Johnson Co
  • New Medicon Pharma Lab
  • MORE
The Hepatorenal Syndrome Treatment market is projected to grow with a CAGR of nearly 6.2% over the forecast period. Hepatorenal syndrome is a type of progressive kidney failure seen in people with severe liver damage, most often caused by cirrhosis. As the kidneys stop functioning, toxins begin to build up in the body. Eventually, this leads to liver failure. The major factor attributing to the growth of the market is increase in prevalence of liver damage and cirrhosis. According to Centers for Disease Control and Prevention, 4.5 million adults are diagnosed with chronic liver disease in the year 2018, in the United States alone. Furthermore, increasing fast-track and orphan drug designations boosts the market growth. However, side effects with the drugs and stringent regulations are restraining the market growth.

Key Market Trends

Therapuetics Segment is the Fastest Growing Segment of the Hepatorenal Syndrome Treatment Market.

Therapeutics segment is expected to grow at a greater phase as the patients prefer taking drugs than undergoing surgeries. Furthermore, increasing fast track and orphan designations to the drugs is further boosting the segment. Several drugs have received orphan drug designation, thereby accelerating their approval process, and this can act as a factor pushing the growth of the therapeutics segment. For instance, in November 2018, BioVie Inc. announced that the FDA has granted Orphan Drug designation to its Terlipressin drug for the treatment of hepatorenal syndrome. The designation for orphan drug allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials, along with seven years of market exclusivity upon regulatory approval. This is likely to drive the hepatorenal syndrome treatment market during the forecast period.

North America Dominates the Market and is Expected to do the Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, established healthcare infrastructure, increased prevalence of severe liver damage and cirrhosis are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and increase in number of research partnerships are some of the drivers expected to increase the market growth. In this region the United States has the maximum share due to supportive healthcare policies, high number of patients, and a developed healthcare market. According to U.S. Department of Health and Human Services,1 in 400 adults in the United States has cirrhosis for the year 2018. As per the statistics the increasing patient pool and increasing disposable revenue in this country boosts the market growth of the region.

Competitive Landscape

The Hepatorenal Syndrome Treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, New Medicon Pharma Lab, Becton, Dickinson and Company, Edwards Lifesciences Corporation, Aetna Inc.,Baxter, Fuji Systems Corp, Johnson & Johnson Co, G Surgiwear Ltd.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4


  • Aetna Inc.
  • Baxter
  • Fuji Systems Corp
  • G Surgiwear Ltd
  • Johnson & Johnson Co
  • New Medicon Pharma Lab
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Severe Liver Damage Which Often Leads to Hepatorenal Syndrome
4.2.2 Increasing Fast Track and Orphan Drug Designations
4.3 Market Restraints
4.3.1 Side-effects and Risks Related to Drug Usage
4.3.2 Stringent Regulatory Requirements
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Treatment
5.1.1 Therapeutics
5.1.2 Liver Transplantation
5.1.3 Surgical Shunting
5.1.4 Renal Replacement Therapy
5.1.5 Others
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.2.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.2.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Cumberland Pharmaceuticals Inc.
6.1.2 Mallinckrodt Pharmaceuticals
6.1.3 New Medicon Pharma Lab
6.1.4 Becton, Dickinson and Company
6.1.5 Edwards Lifesciences Corporation
6.1.6 Aetna Inc.
6.1.7 Baxter
6.1.8 Fuji Systems Corp
6.1.9 Johnson & Johnson Co
6.1.10 G Surgiwear Ltd

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Cumberland Pharmaceuticals Inc.
  • Mallinckrodt Pharmaceuticals
  • New Medicon Pharma Lab
  • Becton, Dickinson and Company
  • Edwards Lifesciences Corporation
  • Aetna Inc.
  • Baxter
  • Fuji Systems Corp
  • Johnson & Johnson Co
  • G Surgiwear Ltd
Note: Product cover images may vary from those shown